Regeneron Pharmaceuticals has reported positive initial results from an ongoing Phase III clinical trial of antibody cocktail REGEN-COV used as a passive vaccine for preventing Covid-19 in people at high risk of infection.
REGEN-COV is a cocktail of two monoclonal antibodies, namely casirivimab and imdevimab (also known as REGN10933 and REGN10987), and can specifically inhibit SARS-CoV-2 infectivity.
Check out the full article right here.